ADC Therapeutics - Press Releases

2020 2019 2018 2017 2016 2015 2014 2013 2012

July 06, 2020

ADC Therapeutics Announces U.S. Food and Drug Administration Has Lifted Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine

June 12, 2020

ADC Therapeutics Announces Maturing Data from Pivotal Phase 2 Clinical Trial and Phase 1/2 Combination Clinical Trial of Loncastuximab Tesirine (Lonca) in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

June 05, 2020

ADC Therapeutics to Host Conference Call to Highlight Loncastuximab Tesirine (Lonca) Clinical Trial Data Being Presented at Virtual EHA Annual Congress

May 21, 2020

ADC Therapeutics Announces Loncastuximab Tesirine (Lonca) Clinical Data to be Presented at the Virtual 25th EHA Annual Congress

May 19, 2020

ADC Therapeutics Announces Closing of Upsized $267 Million Initial Public Offering and Receipt of the $65 Million First Tranche under Its $115 Million Convertible Credit Facility with Deerfield

May 14, 2020

ADC Therapeutics Announces Pricing of Upsized Initial Public Offering

May 11, 2020

ADC Therapeutics Announces Launch of Initial Public Offering

May 01, 2020

ADC Therapeutics Announces a $115 Million Convertible Credit Facility with Deerfield

April 27, 2020

ADC Therapeutics Appoints Victor Sandor, M.D., to Its Board of Directors

April 24, 2020

ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering

April 21, 2020

ADC Therapeutics Appoints Jennifer Creel as Chief Financial Officer

March 19, 2020

ADC Therapeutics to Appoint Ron Squarer as Chairman of Its Board of Directors and an Advisor to the Company

January 10, 2020

ADC Therapeutics Appoints Joseph Camardo, MD, as Head of Medical Affairs

January 09, 2020

ADC Therapeutics Announces Positive Results from Pivotal Phase 2 Clinical Trial of Single Agent Loncastuximab Tesirine (ADCT-402) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma